1. Acknowledgement to Referees

   Acknowledgement to Referees 16 November 2019 Pages: 1141 - 1145

2. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential

   • Lindsay Fox
   • Lewis S. Nelson

   Current Opinion 24 September 2019 Pages: 1147 - 1154

3. Novel IDH1-Targeted Glioma Therapies

   • Georg Karpel-Massler
   • Trang T. T. Nguyen
   • Markus D. Siegelin

   Leading Article 25 November 2019 Pages: 1155 - 1166

   

4. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review

   • Frank M. C. Besag
   • Michael J. Vasey
   • Ian C. K. Wong

   Systematic Review 13 November 2019 Pages: 1167 - 1186

   

5. An Update on Vitamin D and Disease Activity in Multiple Sclerosis

   • Joost Smolders
   • Øivind Torkildsen
   • Trygve Holmøy

   Review Article Open access 04 November 2019 Pages: 1187 - 1199

   

6. Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder

   • Georgios Schoretsanitis
   • Jose de Leon
   • Michael Paulzen

   Review Article 27 November 2019 Pages: 1201 - 1222

7. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)

   • Amichai Perlman
   • Maor Wanounou
   • Mordechai Muszkat

   Short Communication 04 November 2019 Pages: 1223 - 1228

   

8. Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis

   • Maya Golan
   • Karin Mausner-Fainberg
   • Arnon Karni

   Original Research Article 12 November 2019 Pages: 1229 - 1237